<DOC>
	<DOC>NCT00546325</DOC>
	<brief_summary>Primary: To assess the effects of rimonabant on HbA1c in patients with Type 2 diabetes who are overweight or obese (Body Mass Index (BMI) &gt; 27 kg/m² and BMI &lt; 40 kg/m²), have uncontrolled HbA1c (7.0% - 9.0% inclusive) and are currently on maximal tolerated doses of two Oral Anti Diabetic medications - Metformin (Met) and Sulfonylurea (SU). Secondary: To assess the effects of rimonabant on Anthropometric measures, Glucose measures, Lipid measures, Other measures and changes in quality of life</brief_summary>
	<brief_title>REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>List of Inclusion and Exclusion criteria: History of Type 2 diabetes HbA1c between 7% to 9% (inclusive) BMI ≥ 27kg/m² and BMI ≤ 40kg/m² Currently taking Metformin and Sulfonylurea. Uncontrolled serious psychiatric illness such as major depression Current use of antidepressants Severe renal impairment (creatinine clearance less than 30ml/min) Severe hepatic impairment known by investigator or Aspartate Aminotransferase and/or Alanine Aminotransferase &gt; 3 times Upper Limit Normal Patient treated for epilepsy Pregnant or breastfeeding women Women of childbearing potential not protected by effective contraception Hypersentivity/intolerance to rimonabant or any of the excipents Presence of any condition, current or anticipated that in the investigator's opinion would compromise the patient's safety Use of insulin for longer than 1 week within 4 weeks prior to screening Chronic use of systemic corticosteriods Use of glitazone therapy, glucagonlike peptide or dipeptidyl peptidase IV History of drug or alcohol abuse wihtin the last three years Heart failure class IIIIV (New York Heart Association classification) Severe hypertension Adminstration of the following medications: phentermine, amphetamines, orlistat, sibutramine, herbal remedies Use of nonlipid agents known to affect lipid metabolism: retinoids, antiretrovirals, hormone replacement therapy containing estrogens, cyclosporin, thiazolidinediones (glitazones), fish oils, plant sterols Use of ketoconazole, itraconazole, ritonavir, clarithromycin, rifampicin, phenytoin, phenobarbitone, carbamazepine or St John's Wort Participation in a clinical study within the 4 weeks prior to randomisation Patients involved in an existing weight loss program Presence of chronic hepatitis Use, or misuse, of substances of abuse Marijuana or hashish users History of gastrointestinal surgery for weight loss purposes or who are scheduled for such surgery within the duration of their expected participation in this study History or presence of bulimia or laxative abuse NonEnglish speaking The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>